Disappointing. Whilst only one dot ( ..or two inc last week) I cant help feeling more and more that V will be much better served in the hands of a BP, be that a large co-promotion deal or a BO. a successful GIA strategy from a relatively small infrastructure base will be very difficult and AMRN doesn't have a few years to build this up and get this right. V needs to get to market, quick and hard IMHO.
Thank you Sam. I understand that it is performing as previous years, but with all of the revelations of its effectiveness against MACE I am not looking for it to mirror its past performance. If this is to be one of the best selling drugs of all time.
Sam...I feel confident that by March of next year(AFTER FDA approval of Vascepa for expanded indications)...this long standing pattern of March being a low month will be blazingly changed...along with an impressive increase in scripts in the quarters preceding.
Thanks Sam. These are great numbers for Q1. Only 3 weeks until we start reporting on April, etc. Super news from AMRN this week. Now doctors need to go home and start saving even more patient lives.
Anyone have a clue why scrips drop annually in March? We know deductibles have an impact on Jan. sales, but WTF occurs in March that could impact scrips this much?